- TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
- TA226: Lymphoma (follicular non-Hodgkin's) - rituximab
- TA225: Rheumatoid arthritis (after the failure of previous anti-rheumatic drugs) - golimumab
- TA223: Peripheral arterial disease - cilostazol, naftidrofyryl oxalate, pentoxifylline and inositol nicotinate
- TA220: Psoriatic arthritis - golimumab
- TA222: Ovarian cancer (relapsed) - trabectedin
- TA221: Thrombocytopenic purpura - romiplostim
- TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma
- TA217: Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine
- TA214: Breast cancer - bevacizumab (in combination with a taxane)
- : Renal cell carcinoma (first line metastatic) - pazopanib
- TA215: Renal cell carcinoma (first line metastatic) - pazopanib
- TA216: Leukaemia (lymphocytic) - bendamustine
- Schizophrenia - aripiprazole
- Project: SWITCH - Randomised- controlled trial of switching to alternative tumour necrosis factor-blocking drugs or abat
- TA212: Colorectal cancer (metastatic) - bevacizumab
- TA211: Constipation (women) - prucalopride
- TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (Review of TA90)
- Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
- TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
- TA205: Thrombocytopenic purpura - eltrombopag
- TA203: Liraglutide for the treatment of type 2 diabetes mellitus
- Osteoporotic fractures - denosumab
- TA201: Asthma (in children) - omalizumab
- TA202: Chronic lymphocytic leukaemia - ofatumumab
- TA200: Hepatitis C - peginterferon alfa and ribavirin
- TA196: Gastrointestinal stromal tumours - imatinib (adjuvant)
- TA197: Atrial fibrillation - dronedarone
- TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
- TA198: Rheumatoid arthritis - tocilizumab
- TA192: Lung cancer (non-small-cell, first line) - gefitinib
- TA194: Bone loss (therapy-induced) in non-metastatic prostate cancer - denosumab (terminated appraisal)
- TA191: Gastric cancer (advanced) - capecitabine
- TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
- TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
- TA26: Lung cancer - docetaxel, paclitaxel, gemcitabine and vinorelbine (replaced by CG24 Lung cancer)
- : Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
- TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
- TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
- TA141: Rheumatoid arthritis (refractory) - abatacept
- TA140: Ulcerative colitis (subacute manifestations) - infliximab
- TA143: Ankylosing spondylitis - adalimumab, etanercept and infliximab
- TA142: Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin
- TA147: Breast cancer (advanced & metastatic) - bevacizumab (terminated appraisal)
- TA148: Lung cancer (non-small-cell) - bevacizumab (terminated appraisal)
- TA149: Glioma (recurrent) - carmustine implants (terminated appraisal)
- TA150: Colorectal cancer (metastatic) - cetuximab (terminated appraisal)
- TA146: Psoriasis - adalimumab
- TA145: Head and neck cancer - cetuximab
- TA151: Diabetes - insulin pump therapy
- TA138: Asthma (in adults) - corticosteroids
- TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
- TA124: Lung cancer (non-small-cell) - pemetrexed
- TA126: Rheumatoid arthritis (refractory) - rituximab
- TA111: Alzheimer's disease - donepezil, galantamine, rivastigmine (review) and memantine
- TA130: Rheumatoid arthritis - adalimumab, etanercept and infliximab
- TA129: Multiple myeloma - bortezomib
- TA125: Psoriatic arthritis (moderate to severe) - adalimumab
- TA132: Hypercholesterolaemia - ezetimibe
- TA133: Asthma (uncontrolled) - omalizumab
- TA131: Asthma (in children) - corticosteroids
- TA134: Psoriasis - infliximab
- TA135: Mesothelioma - pemetrexed disodium
- TA153: Hepatitis B - entecavir
- TA154: Hepatitis B - telbivudine
- TA155: Macular degeneration (age-related) - ranibizumab and pegaptanib
- TA177: Eczema (chronic) - alitretinoin
- TA178: Renal cell carcinoma
- TA176: Colorectal cancer (first line) - cetuximab
- TA179: Gastrointestinal stromal tumours - sunitinib
- TA180: Psoriasis - ustekinumab
- TA182: Acute coronary syndrome - prasugrel
- TA183: Cervical cancer (recurrent) - topotecan
- TA184: Lung cancer (small-cell) - topotecan
- TA185: Soft tissue sarcoma - trabectedin
- TA186: Rheumatoid arthritis - certolizumab pegol
- TA173: Hepatitis B - tenofovir disoproxil fumarate
- TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
- TA175: Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal)
- TA158: Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir
- TA160: Osteoporosis - primary prevention
- TA161: Osteoporosis - secondary prevention including strontium ranelate
- TA162: Lung cancer (non-small-cell) - erlotinib
- TA163: Ulcerative colitis (acute exacerbations) - infliximab
- TA164: Hyperuricaemia - febuxostat
- TA168: Influenza - zanamivir, amantadine and oseltamivir (review)
- TA169: Renal cell carcinoma - sunitinib
- TA171: Multiple myeloma - lenalidomide
- TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
- TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
- TA32: Multiple sclerosis - beta interferon and glatiramer acetate
- TA55: Ovarian cancer - paclitaxel (review)
- TA61: Colorectal cancer - capecitabine and tegafur uracil
- TA62: Breast cancer - capecitabine (replaced by CG81)
- TA64: Growth hormone deficiency (adults) - human growth hormone
- TA65: Non-Hodgkin's lymphoma - rituximab
- TA67: Flu prevention - amantadine and oseltamivir (replaced by TA158)
- TA68: Macular degeneration (age-related) - photodynamic therapy
- TA70: Leukaemia (chronic myeloid) - imatinib
- TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
- TA79: Epilepsy (children) - newer drugs
- TA80: Acute coronary syndromes - clopidogrel
- TA54: Breast cancer - vinorelbine (replaced by CG81)
- TA53: Diabetes (types 1 and 2) - long acting insulin analogues
- TA29: Leukaemia (lymphocytic) - fludarabine
- TA36: Rheumatoid arthritis - etanercept and infliximab (Partially replaced by TA130)
- TA47: Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review)
- TA25: Pancreatic cancer - gemcitabine
- TA20: Motor neurone disease - riluzole
- TA23: Brain cancer - temozolomide
- TA43: Schizophrenia - atypical antipsychotics (replaced by CG82)
- TA30: Breast cancer - taxanes (review)(replaced by CG81)
- TA34: Breast cancer - trastuzumab
- TA40: Crohn's disease - infliximab
- TA35: Arthritis (juvenile idiopathic) - etanercept
- TA42: Growth hormone deficiency (children) - human growth hormone
- TA82: Atopic dermatitis (eczema) - pimecrolimus and tacrolimus
- TA81: Atopic dermatitis (eczema) - topical steroids
- TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
- TA108: Breast cancer (early) - paclitaxel
- TA110: Follicular lymphoma - rituximab
- TA112: Breast cancer (early) - hormonal treatments
- TA113: Diabetes (type 1 and 2) - inhaled insulin
- TA115: Drug misuse - naltrexone
- TA114: Drug misuse - methadone and buprenorphine
- TA117: Hyperparathyroidism - cinacalcet
- TA116: Breast cancer - gemcitabine
- TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
- TA119: Leukaemia (lymphocytic) - fludarabine
- TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
- TA109: Breast cancer (early) - docetaxel
- TA106: Hepatitis C - peginterferon alfa and ribavirin
- TA107: Breast cancer (early) - trastuzumab
- TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
- TA90: Vascular disease - clopidogrel and dipyridamole
- TA93: Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (review)
- TA94: Cardiovascular disease - statins
- TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
- TA98: Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review)
- TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
- TA99: Renal transplantation - immunosuppressive regimens for children and adolescents
- TA101: Prostate cancer (hormone-refractory) - docetaxel
- TA103: Psoriasis - efalizumab and etanercept
- TA104: Psoriatic arthritis - etanercept and infliximab
- TA127: Multiple sclerosis - natalizumab
- TA185: Soft tissue sarcoma - trabectedin
- TA186: Rheumatoid arthritis - certolizumab pegol
- TA184: Lung cancer (small-cell) - topotecan
- TA182: Acute coronary syndrome - prasugrel
- TA183: Cervical cancer (recurrent) - topotecan
- TA180: Psoriasis - ustekinumab
- TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
- TA179: Gastrointestinal stromal tumours - sunitinib
- TA178: Renal cell carcinoma
- TA177: Eczema (chronic) - alitretinoin
- TA176: Colorectal cancer (first line) - cetuximab
- National Quality Forum endorses 18 medication management measures
- Publication: Volume 13, number 34 (Ara). Study found that rosuvastatin 40 mg/day is the most effective treatment in term
- Publication: Volume 13, number 35 (Jones). Study found that both adefovir dipivoxil and pegylated interferon alpha are b
- TA173: Hepatitis B - tenofovir disoproxil fumarate
- TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
- NICE issues updated Type 2 diabetes guidelines
- TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
- TA171: Multiple myeloma - lenalidomide
- TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
- TA36: Rheumatoid arthritis - etanercept and infliximab (Partially replaced by TA130)
- TA168: Influenza - zanamivir, amantadine and oseltamivir (review)
- CADTH issues guidelines in the management of neuropathic pain
- TA163: Ulcerative colitis (acute exacerbations) - infliximab
- TA162: Lung cancer (non-small-cell) - erlotinib
- TA160: Osteoporosis - primary prevention
- TA161: Osteoporosis - secondary prevention including strontium ranelate
- Autologous Progenitor Cell Therapy for the Treatment of Ischemic Heart Disease
- NICE Issues Guidance on Two Injectable AMD Products Approved by the FDA
- NICE Issues Technology Appraisals on Two Oral Hep B Products Approved by the FDA
- NICE issues guidance on sequential use of anti-TNFs
- Cognitive Rehabilitation for Traumatic Brain Injury in Adults
- Pharmacogenomics-Based Treatment of Helicobacter pylori Infection
- CYP2D6 Pharmacogenomics of Tamoxifen Treatment
- Off-Label Uses of Sorafenib and Sunitinib